Product logins

Find logins to all Clarivate products below.


Related Market Assessment Reports

Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Myasthenia Gravis – Unmet Need – Unmet Need – Generalized Myasthenia Gravis (US/EU)
Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…
Report
Parkinson’s Disease – Current Treatment – Current Treatment: Physician Insights – Parkinson’s Disease (US)
The mature Parkinson’s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie’s Vyalev, Supernus’s Onapgo), extended-release levodopa formulations (i.e.,…
Report
Epilepsy – Unmet Need – Unmet Need – Epilepsy: Generalized-Onset Seizures (US/EU)
Generalized onset seizures (GOS) originate simultaneously in both hemispheres of the brain and account for nearly 40% of all epilepsy cases. Current management relies primarily on widely used…